The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open-label, single-dose, parallel-group study.

ABSTRACT:

Objective

The objective of this study was to investigate the pharmacokinetics of rimegepant in participants with mild, moderate, or severe renal impairment compared to healthy adults with normal renal function.

Background

Rimegepant is a calcitonin gene-related peptide receptor antagonist approved in the United States for treatment of acute and preventive treatment of migraine.

Methods

In this Phase 1, open-label, four-group, pharmacokinetic study, 36 participants were grouped by degree of renal impairment according to estimated glomerular filtration rate (eGFR): normal; mild (60-89 mL/min/1.73 m²); moderate (30-59 mL/min/1.73 m²); and severe (<30 mL/min/1.73 m²). Participants received a single 75-mg oral rimegepant tablet to determine

SUBMITTER: Bhardwaj R 

PROVIDER: S-EPMC12455468 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature